NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
1 . A method of treating acute agitation associated with schizophrenia or bipolar I or II disorder in a human subject, the method comprising:
administering an oromucosal formulation with an initial dose of dexmedetomidine or a pharmaceutically acceptable salt thereof to the human subject;
administering the oromucosal formulation with a second dose of dexmedetomidine or the pharmaceutically acceptable salt thereof to the human subject at least two hours after and within 24 hours of the initial dose; and
optionally administering the oromucosal formulation with a third dose of dexmedetomidine or the pharmaceutically acceptable salt thereof to the human subject at least two hours after the second dose and within 24 hours of the initial dose;
wherein the administration of the dexmedetomidine does not exceed a maximum total 24 hour daily dosage;
wherein the initial dose, the second dose, the optional third dose, and the maximum total 24 hour daily dosage are 120 mcg, 60 mcg, 60 mcg, and 240 mcg of dexmedetomidine, respectively; and
wherein the human subject is older than 65 years of age and the agitation is severe.
2 . (canceled)
3 . (canceled)
4 . The method of claim 1 , wherein
severe agitation is defined by a Positive and Negative Syndrome Scale-Excited Component (PEC) score of 20 or higher.
5 . The method of claim 1 , wherein the third dose is administered at least two hours after the second dose and within 24 hours of the initial dose.
6 . (canceled)
7 . (canceled)
8 . The method of claim 4 , wherein the third dose is administered at least two hours after the second dose and within 24 hours of the initial dose.
9 . The method of claim 1 , wherein the oromucosal formulation further comprises at least one water-soluble polymer.
10 . The method of claim 9 , wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof.
11 . The method of claim 10 , wherein the at least one water-soluble polymer is hydroxypropyl cellulose.
12 . The method of claim 1 , wherein the human subject does not have a hepatic impairment.
13 . (canceled)
14 . (canceled)
15 . The method of claim 12 , wherein
severe agitation is defined by a PEC score of 20 or higher.
16 . The method of claim 12 , wherein the third dose is administered at least two hours after the second dose and within 24 hours of the initial dose.
17 . (canceled)
18 . (canceled)
19 . The method of claim 15 , wherein the third dose is administered at least two hours after the second dose and within 24 hours of the initial dose.
20 . The method of claim 12 , wherein the oromucosal formulation further comprises at least one water-soluble polymer.
21 . The method of claim 20 , wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof.
22 . The method of claim 21 , wherein the at least one water-soluble polymer is hydroxypropyl cellulose.
23 . A method of treating acute agitation associated with schizophrenia or bipolar I or II disorder in a human subject, the method comprising:
administering an oromucosal formulation with an initial dose of dexmedetomidine or a pharmaceutically acceptable salt thereof to the human subject;
administering the oromucosal formulation with a second dose of dexmedetomidine or the pharmaceutically acceptable salt thereof to the human subject at least two hours after and within 24 hours of the initial dose; and
optionally administering the oromucosal formulation with a third dose of dexmedetomidine or the pharmaceutically acceptable salt thereof to the human subject at least two hours after the second dose and within 24 hours of the initial dose;
wherein the administration of the dexmedetomidine does not exceed a maximum total 24 hour daily dosage;
wherein the human subject is older than 65 years of age and the agitation is severe;
instructing the following:
(a) the initial dose, the second dose, the optional third dose, and the maximum total 24 hour daily dosage are 120 mcg, 60 mcg, 60 mcg, and 240 mcg of dexmedetomidine, respectively, and said initial dose, second dose, and optional third dose are administered to said human subject up to said maximum total 24 hour daily dose, and
(b) cutting the oromucosal formulation with the first dose in half to provide the oromucosal formulation with the second dose and the optional third dose.
24 . The method of claim 23 , wherein the third dose is administered at least two hours after the second dose and within 24 hours of the initial dose.
25 . The method of claim 23 , wherein the oromucosal formulation further comprises at least one water-soluble polymer.
26 . The method of claim 25 , wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof.
27 . The method of claim 26 , wherein the at least one water-soluble polymer is hydroxypropyl cellulose.
28 . The method of claim 23 , wherein the human subject does not have a hepatic impairment.